This medication is taken by intravenous (IV) infusion.
Ocrevus® is a humanized monoclonal antibody that targets CD20 positive B lymphocytes ( a type of white blood cell), which contribute to nerve damage in MS.
Ocrevus is approved by the FDA for the treatment relapsing forms of multiple sclerosis in adults, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses). Ocrevus is also approved by the FDA to treat primary progressive MS in adults.
Click to read the Prescribing Information for healthcare professionals.
Click to read the Medication Guide for patients.
Financial Assistance ProgramGenentech® Access Solutions